VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes-Reference-Cited by-同舟云学术

VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes

Published:2022-09-14 Issue:1 Volume:95 Page:
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:Journal of Medical Virology

Author:

Shen Yinan¹²,Song Wei²,Lin Danni¹²,Zhang Xiaozhen¹²,Wang Meng¹²,Li Yuwei¹²^ORCID,Yang Zifan²,Guo Sida³,Wang Zijun³,Sheng Jianpeng²,Murad Yanal⁴,Ding Jun⁵,Lou Yufeng³,Pan Xinping⁶,Wu Zongsong⁵,Zhao Ronghua⁴⁵⁶,Jia Weiguo⁴⁵⁶,Bai Xueli¹²,Liang Tingbo¹²

Affiliation:

1. Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital，Zhejiang University School of Medicine Hangzhou China

2. Zhejiang Provincial Key Laboratory of Pancreatic Disease The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China

3. Center for Innovation & Translational Medicine The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China

4. Virogin Biotech Canada Ltd. Vancouver British Columbia Canada

5. Shanghai Virogin Biotech Co. Ltd. Shanghai China

6. CNBG‐Virogin Biotech (Shanghai) Co. Ltd. Shanghai China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject